Celltrion Unveils World’s First Quadruple-Agonist Obesity Drug Candidate, CT-G32/SCO-940

Celltrion has announced the development of CT-G32/SCO-940, a quadruple-agonist obesity drug candidate that targets four hormonal pathways simultaneously: GLP-1, GIP, glucagon, and amylin. This innovative approach, unveiled at TIDES Europe in Amsterdam, sets it apart from existing treatments, which typically focus on dual or triple agonist mechanisms.

Preclinical studies conducted in collaboration with SCOHIA PHARMA have shown promising results, with CT-G32/SCO-940 demonstrating greater weight-loss effects and better preservation of lean body mass compared to a leading triple-agonist drug in animal models. The drug candidate also exhibited a reduction in elevated blood insulin levels, suggesting potential applications in treating metabolic diseases.

Celltrion plans to submit an IND application to the FDA by February 2027, with the goal of initiating clinical trials in the second quarter of 2027. If successful, CT-G32/SCO-940 could represent a first-in-class treatment for obesity, addressing unmet needs in current care.

Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.